Disease · MONDO_0005041

glaucoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. glaucoma. Diseases, record MONDO_0005041. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005041

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: glaucoma; Open Targets
Open Targets ID: MONDO_0005041; Open Targets
Other names: GLAUCOMA NEC, Glaucoma (disorder), Glaucoma NOS, Glaucoma NOS (disorder), Glaucoma associated with other ocular disorders, Glaucoma associated with other ocular disorders (disorder), Glaucoma associated with other ocular disorders NOS, Glaucoma associated with other ocular disorders NOS (disorder), Glaucomas, Other specified forms of glaucoma, Other specified forms of glaucoma (disorder), Other specified glaucoma, Other specified glaucoma NOS, Other specified glaucoma NOS (disorder), Unspecified glaucoma, glaucoma (disease); Open Targets
Disease Ontology: DOID:1686; Disease Ontology
MeSH: D005901; MeSH
NCI Thesaurus: C26782; NCI Thesaurus
Highest stage of its drugs: Approval, for 47 of its 93 drugs, from ATC, DailyMed and PMDA; Open Targets

Drugs93

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TIMOLOL	CHEMBL499	Small molecule	Approval	ATC, DailyMed and PMDA	48	36	34	Drugs and targets
LATANOPROST	CHEMBL1051	Small molecule	Approval	ATC, DailyMed and PMDA	39	33	33	Drugs and targets
BIMATOPROST	CHEMBL1200963	Small molecule	Approval	ATC and PMDA	32	30	30	Drugs and targets
BRIMONIDINE	CHEMBL844	Small molecule	Approval	ATC	19	18	16	Drugs and targets
TRAVOPROST	CHEMBL1200799	Small molecule	Approval	ATC and PMDA	19	16	16	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Approval	DailyMed and PMDA	17	15	15	Drugs and targets
TIMOLOL MALEATE	CHEMBL1200870	Small molecule	Approval	DailyMed and PMDA	22	12	11	Drugs and targets
BRIMONIDINE TARTRATE	CHEMBL1200389	Small molecule	Approval	DailyMed and PMDA	15	9	8	Drugs and targets
BRINZOLAMIDE	CHEMBL220491	Small molecule	Approval	ATC and PMDA	11	7	7	Drugs and targets
DORZOLAMIDE	CHEMBL218490	Small molecule	Approval	ATC	7	6	6	Drugs and targets

1 to 10 of 93

See all 93 drugs

Targets118

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	12	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	10	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor mRNA RNAi inhibitor	Approval	https://conductscience.org/library/genes/154	Drugs and targets
ADRA2A	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	7	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
CA2	Carbonic anhydrase 2	7	Carbonic anhydrase II inhibitor	Approval	https://conductscience.org/library/genes/760	Drugs and targets
NR3C1	Glucocorticoid receptor	7	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ACHE	Acetylcholinesterase	5	Acetylcholinesterase inhibitor	Approval	https://conductscience.org/library/genes/43	Drugs and targets
ADRB3	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-3 adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets
PTGFR	Prostaglandin F2-alpha receptor	5	Prostanoid FP receptor agonist	Approval	https://conductscience.org/library/genes/5737	Drugs and targets

1 to 10 of 118

See all 118 targets

Trials157

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01298700	Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 4	806	2018-09-17	Glaucoma, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT01191008	Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension		661	2017-07-17	Glaucoma, Ocular Hypertension	LATANOPROST, TIMOLOL, TIMOLOL MALEATE	Its record names the disease	ClinicalTrials.gov
NCT01099774	Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3	597	2012-04-27	Glaucoma, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT00541242	Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension	Phase 4	586	2011-10-27	Ocular Hypertension, Glaucoma	BIMATOPROST, LATANOPROST	Its record names the disease	ClinicalTrials.gov
NCT01177098	Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3	561	2013-03-12	Glaucoma, Ocular Hypertension	BIMATOPROST, TIMOLOL	Its record names the disease	ClinicalTrials.gov
NCT03825380	Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients	Phase 3	485	2023-11-21	Ocular Hypertension, Glaucoma	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT00449956	MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)	Phase 3	474	2009-05-29	Glaucoma	DORZOLAMIDE HYDROCHLORIDE, TIMOLOL MALEATE	Its record names the disease	ClinicalTrials.gov
NCT01830140	A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension	Phase 3	466	2015-05-06	Glaucoma, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT03691649	A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study	Phase 3	426	2023-08-30	Glaucoma and Ocular Hypertension	OMIDENEPAG ISOPROPYL, TIMOLOL MALEATE	Its record names the disease	ClinicalTrials.gov
NCT03691662	A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study	Phase 3	417	2023-08-09	Glaucoma and Ocular Hypertension	OMIDENEPAG ISOPROPYL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 157

See all 157 trials

Comparisons in its trials53

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bimatoprost 0.03% Eye Drops vs Latanoprost 0.005% Eye Drops: serious adverse events	4 of 269	11 of 586	855	NCT00541242	Trial comparisons
Bimatoprost 0.01% Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events	45 of 400	40 of 398	798	NCT01298700	Trial comparisons
Bimatoprost 0.03% Formulation B Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events	2 of 301	5 of 295	596	NCT01099774	Trial comparisons
Bimatoprost/Timolol Formulation A vs Bimatoprost/Timolol Fixed Combination Ophthalmic Solution: serious adverse events	4 of 278	4 of 282	560	NCT01177098	Trial comparisons
T4032 vs Lumigan®: deaths from any cause	0 of 236	0 of 249	485	NCT03825380	Trial comparisons
T4032 vs Lumigan®: serious adverse events	1 of 236	2 of 249	485	NCT03825380	Trial comparisons
Bimatoprost 0.01% vs Bimatoprost 0.03%: serious adverse events	2 of 233	2 of 233	466	NCT01830140	Trial comparisons
DE-117 Ophthalmic Solution vs Timolol Maleate Ophthalmic Solution 0.5%: deaths from any cause	1 of 204	0 of 205	409	NCT03691662	Trial comparisons
DE-117 Ophthalmic Solution vs Timolol Maleate Ophthalmic Solution 0.5%: serious adverse events	7 of 204	1 of 205	409	NCT03691662	Trial comparisons
Bimatoprost vs Travoprost: serious adverse events	1 of 131	0 of 133	264	NCT00440011	Trial comparisons

1 to 10 of 53

See all 53 comparisons in its trials

Papers from its trials58

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32622848	RESULT	1	PubMed
32564453	RESULT	1	PubMed
31823206	RESULT	1	PubMed
31727428	RESULT	1	PubMed
31611797	RESULT	1	PubMed
29849435	RESULT	1	PubMed
29477688	RESULT	1	PubMed
28797892	RESULT	1	PubMed
28617732	RESULT	1	PubMed
25826644	RESULT	1	PubMed

1 to 10 of 58

See all 58 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005041

GET https://conductscience.org/api/diseases/v1/MONDO_0005041/drugs?page=2

API reference For AI assistants